The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi
Research Funding - novartis (Inst); pfizer (Inst)
 
Wanling Xie
No Relationships to Disclose
 
Yu-Hui Chen
No Relationships to Disclose
 
Jean-Marie Boher
Stock and Other Ownership Interests - Sanofi
Other Relationship - Sanofi
 
Loana Bueno Valenca
No Relationships to Disclose
 
Brandon David Bernard
No Relationships to Disclose
 
Stephane Culine
No Relationships to Disclose
 
Muriel Habibian
No Relationships to Disclose
 
Michael Anthony Carducci
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Medivation
Research Funding - Amgen (Inst)
 
Robert S. DiPaola
No Relationships to Disclose
 
Glenn Liu
Research Funding - Cellectar (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
Other Relationship - Alliance HealthCare Services
 
Mark Pomerantz
No Relationships to Disclose
 
Mari Nakabayashi
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi
 
Karim Fizazi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Curevac; Dendreon; Ipsen; Janssen Oncology; Novartis; Orion; Sanofi; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Janssen Oncology; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Gwenaelle Gravis
Consulting or Advisory Role - Sanofi
Expert Testimony - Sanofi
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination